Why the study?
Inflammation leads to atherosclerosis and ACS, but the association between inflammatory markers and platelet reactivity in patients treated with potent P2Y12 inhibitors was unclear.
Does inflammatory state affect the antiplatelet efficacy of potent P2Y12 inhibitors in patients with ACS?
Does inflammatory state affect the antiplatelet efficacy of potent P2Y12 inhibitors in patients with ACS?
The inflammatory state does not significantly affect the antiplatelet efficacy of potent P2Y12 inhibitors like ticagrelor and prasugrel in the acute phase of ACS.
Answers are grounded in this paper and cite their sources.
Inflammatory markers should not yet guide P2Y12 inhibitor choice in ACS; leaves open effects in other populations or with different agents.
Inflammation leads to atherosclerosis and acute coronary syndromes (ACS). We performed a prospective, observational study to assess association between the concentrations of inflammatory markers (high sensitivity C-reactive protein, hsCRP; high sensitivity interleukin6, hsIL-6; soluble CD40 ligand, sCD40 L) and platelet reactivity in 338 patients with ACS treated with ticagrelor and prasugrel. We also assessed whether hsCRP, hsIL-6, and sCD40 L are associated with standard inflammatory markers (white blood cell [WBC] and fibrinogen), and whether they differ according to patient diabetic status and pre-treatment with statins. Concentrations of hsCRP and concentrations of hsIL-6 and sCD40 L were assessed using turbidimetric assay and enzyme-linked immunosorbent assay, respectively. Platelet reactivity was measured using multiple electrode aggregometry. There was only a weak inverse correlation between hsIL-6 and platelet reactivity (r≤-0.125). In contrast, concentration of hsIL6 and hsCRP positively correlated with WBC and fibrinogen (r ≥ 0.199). Insulin-dependent diabetes mellitus (IDDM) was associated with higher concentration of hsIL-6 (p = .014), whereas pre-treatment with statins – with lower concentration of hsIL-6 (p = .035). In conclusion, inflammatory state does not affect the antiplatelet efficacy of potent P2Y12 inhibitors in the acute phase of ACS, confirming the safety and efficacy of potent P2Y12 inhibitors in patients with a high inflammatory burden.
No takes yet. Share an insight, caveat, or question.
Biesinger et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: